Neumonco™ – a new modality for cancer treatment

Neumonco™ are mCBMs, in development for the treatment of cancer. In vitro data have demonstrated that mCBMs target and enter cancer cells, reducing cell proliferation, migration, metabolism and differentiation. The Company is currently demonstrating efficacy in-vivo models and is expecting to identify a candidate for clinical development.